Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 18,793 shares at $32.94 ($631K) on 2021-02-23, disclosed to the SEC on 2021-02-25.
Open-market sale of $631k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.87 | 707 | $23K | 3.6% |
| 2 | $32.94 | 1,575 | $52K | 8.2% |
| 3 | $32.94 | 1,575 | $52K | 8.2% |
| 4 | $33.73 | 7,218 | $243K | 38.6% |
| 5 | $33.73 | 7,218 | $243K | 38.6% |
| 6 | $35.40 | 500 |
| $18K |
| 2.8% |
| Total | $33.57 avg | 18,793 | $631K | 100% |
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |